# Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer

> **NCT07530445** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 40 (estimated)

## Conditions studied

- Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer

## Interventions

- **DRUG:** Drug: QL1706 5mg/kg, iv drip,d1,Q3W; Albumin-Bound Paclitaxel 125mg/m2, iv drip, d1、d8, Q3W; Lenvatinib 8mg, po, QD

## Key facts

- **NCT ID:** NCT07530445
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-23
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07530445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07530445, "Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07530445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*